BAKER BROS. ADVISORS LP: MADRIGAL PHARMACEUTICALS INC (MDGL): Quarterly 13F Position History
As of Q1 2026, BAKER BROS. ADVISORS LP reported 2,141,701 shares of MADRIGAL PHARMACEUTICALS INC (MDGL), worth $1.1B and representing 6.4% of its 13F equity book. The position first appeared in Q3 2016 and has been disclosed across 39 13F-HR filings in Pactolio's tracked window.
- 2,141,701Shares Held (Latest Filing)
- $1.1BReported Market Value (Latest Filing)
- 6.4%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$126.1MQuarter-over-Quarter Value Change
- 2,141,701Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 39 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 2,141,701 | 0 | — | $1.1B | 6.4% | $523.5 |
| Q4 2025 | 2,141,701 | 0 | — | $1.2B | 7.3% | $582.3 |
| Q3 2025 | 2,141,701 | +165,683 | +8.4% | $982.3M | 7.1% | $458.7 |
| Q2 2025 | 1,976,018 | +1,428 | +0.1% | $598.0M | 5.8% | $302.6 |
| Q1 2025 | 1,974,590 | 0 | — | $654.0M | 7.2% | $331.2 |
| Q4 2024 | 1,974,590 | 0 | — | $609.3M | 6.5% | $308.6 |
| Q3 2024 | 1,974,590 | 0 | — | $419.0M | 4.3% | $212.2 |
| Q2 2024 | 1,974,590 | +4,792 | +0.2% | $553.2M | 7.1% | $280.2 |
| Q1 2024 | 1,969,798 | 0 | — | $526.0M | 6.6% | $267.0 |
| Q4 2023 | 1,969,798 | +424,685 | +27.5% | $455.8M | 5.2% | $231.4 |
| Q3 2023 | 1,545,113 | 0 | — | $225.6M | 1.3% | $146.0 |
| Q2 2023 | 1,545,113 | 0 | — | $356.9M | 2.1% | $231.0 |
| Q1 2023 | 1,545,113 | 0 | — | $374.3M | 2.0% | $242.3 |
| Q4 2022 | 1,545,113 | +45,900 | +3.1% | $448.5M | 2.7% | $290.3 |
| Q3 2022 | 1,499,213 | 0 | — | $97.4M | 0.6% | $65.0 |
| Q2 2022 | 1,499,213 | 0 | — | $107.3M | 0.6% | $71.6 |
| Q1 2022 | 1,499,213 | 0 | — | $147.1M | 0.8% | $98.1 |
| Q4 2021 | 1,499,213 | 0 | — | $127.0M | 0.6% | $84.7 |
| Q3 2021 | 1,499,213 | 0 | — | $119.6M | 0.5% | $79.8 |
| Q2 2021 | 1,499,213 | 0 | — | $146.0M | 0.6% | $97.4 |
| Q1 2021 | 1,499,213 | 0 | — | $175.4M | 0.8% | $117.0 |
| Q4 2020 | 1,499,213 | 0 | — | $166.7M | 0.6% | $111.2 |
| Q3 2020 | 1,499,213 | +1 | +0.0% | $178.0M | 0.7% | $118.7 |
| Q2 2020 | 1,499,212 | 0 | — | $169.8M | 0.7% | $113.3 |
| Q1 2020 | 1,499,212 | +329,934 | +28.2% | $100.1M | 0.6% | $66.8 |
| Q4 2019 | 1,169,278 | 0 | — | $106.5M | 0.6% | $91.1 |
| Q3 2019 | 1,169,278 | 0 | — | $100.8M | 0.7% | $86.2 |
| Q2 2019 | 1,169,278 | 0 | — | $122.6M | 0.8% | $104.8 |
| Q1 2019 | 1,169,278 | 0 | — | $146.5M | 0.9% | $125.3 |
| Q4 2018 | 1,169,278 | 0 | — | $131.8M | 1.1% | $112.7 |
| Q3 2018 | 1,169,278 | 0 | — | $250.4M | 1.6% | $214.1 |
| Q2 2018 | 1,169,278 | +553,594 | +89.9% | $327.0M | 2.5% | $279.7 |
| Q1 2018 | 615,684 | 0 | — | $71.9M | 0.6% | $116.8 |
| Q4 2017 | 615,684 | +557,922 | +965.9% | $56.5M | 0.5% | $91.8 |
| Q3 2017 | 57,762 | 0 | — | $2.6M | 0.0% | $45.0 |
| Q2 2017 | 57,762 | 0 | — | $939.0K | 0.0% | $16.3 |
| Q1 2017 | 57,762 | 0 | — | $890.0K | 0.0% | $15.4 |
| Q4 2016 | 57,762 | 0 | — | $861.0K | 0.0% | $14.9 |
| Q3 2016 | 57,762 | — | — | $732.0K | 0.0% | $12.7 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did BAKER BROS. ADVISORS LP first disclose a MDGL position in 13F-HR filings?
BAKER BROS. ADVISORS LP first reported MADRIGAL PHARMACEUTICALS INC (MDGL) on its 13F-HR filing for the period ending 2016-09-30 (Q3 2016). The position has appeared on 39 reported quarters within Pactolio's tracked window.
What was BAKER BROS. ADVISORS LP's most recent quarter-over-quarter share-count change in MDGL?
BAKER BROS. ADVISORS LP held the same 2,141,701 shares of MDGL between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent BAKER BROS. ADVISORS LP's cost basis in MDGL?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.